HI
FULC icon

Harbour Investments’s Fulcrum Therapeutics FULC Stock Holding History

Harbour Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,165
Closed -$4.16K – 3528
2024
Q3 		$4.16K Hold
1,165
– – ﹤0.01% 2689
2024
Q2 		$7.22K Buy
+1,165
New +$8.82K ﹤0.01% 2385

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Harbour Investments's FULC Position: Q4 2024 in Review

Harbour Investments sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 1,165 shares — an estimated $4.16K sold.

Harbour Investments first reported a position in FULC in Q2 2024 and held it in 2 quarters. The position peaked at $7.22K in Q2 2024. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Harbour Investments reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Harbour Investments sold 1,165 Fulcrum Therapeutics shares in Q4 2024, an estimated $4.16K.
  • Harbour Investments first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 2 quarters.
  • Harbour Investments's Fulcrum Therapeutics position peaked at $7.22K in Q2 2024.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Harbour Investments's 13F filing for Q4 2024, filed 10 Feb 2025.